Susan Krumplitsch

Susan Krumplitsch represents life science companies in intellectual property disputes, with an emphasis on patent and trade secret litigation. Her clients include innovative biotechnology, pharmaceutical and medical device companies and she regularly appears in federal courts across the country and in post-grant review proceedings at the US Patent and Trademark Office.

Her practice involves a wide variety of technologies, including next-generation DNA sequencing, therapeutic monoclonal antibodies, transgenic animals, pharmaceutical formulations, small molecule drug compounds, mammalian cell lines, biofuels, fungicides and medical imaging. Susan also advises clients on complex patent strategies and is a frequent publisher and speaker on intellectual property issues surrounding the life science industry's increasing adoption of artificial intelligence technology.

Susan is a member of the Board of Directors of BIOCOM, the association representing the California life science industry.

Susan serves as a member of DLA Piper’s Northern California Pro Bono Committee. She also has significant pro bono experience representing asylum applicants and drafting immigration-related amicus briefs for various US Circuit Courts of Appeal and the Supreme Court of the United States.